The switch from conventional to atypical antipsychotic treatment should not be based exclusively on the presence of cognitive deficits. A pilot study in individuals with schizophrenia

BMC Psychiatry

Volumn 10, Issue , 2010, Pages

  Selva Vera, Gabriel ^a,b   Balanzá Martínez, Vicent ^a,b   Salazar Fraile, José ^a,b   Sánchez Moreno, José ^b,c   Martinez Aran, Anabel ^b,c   Correa, Patricia ^a,b   Vieta, Eduard ^b,c   Tabarés Seisdedos, Rafael ^a,b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; LONG TERM CARE; MALE; NATURALISTIC INQUIRY; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; SCHIZOPHRENIA; VERBAL BEHAVIOR; VERBAL MEMORY; VISUAL MEMORY; CLASSIFICATION; COMORBIDITY; COMPARATIVE STUDY; LONGITUDINAL STUDY; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; RETROSPECTIVE STUDY; STATISTICS; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; COMORBIDITY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; NEUROPSYCHOLOGICAL TESTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77953380176     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-10-47     Document Type: Article

References (46)

1. Daban C, Martinez-Aran A, Torrent C, Tabarés-Seisdedos R, Balanza-Martínez V, Salazar-Fraile J, Selva-Vera G, Vieta E. Specificity of cognitive deficits in bipolar disorder versus schizophrenia. A systematic review. Psychother Psychosom 2006, 75:72-84. 10.1159/000090891, 16508342.
2. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999, 156:544-549.
3. Hill SK, Harris MS, Herbner ES, Pavuluri M, Sweeney JA. Cognitive allied phenotypes for schizophrenia and bipolar disorder. Schizophr Bull 2008, 34:743-759. 10.1093/schbul/sbn027, 2632447, 18448479.
4. Daban C, Amado I, Bourdel MC, Loo H, Olié JP, Poirier MF, Krebs MO. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. J Psychiatr Res 2005, 39:391-398. 10.1016/j.jpsychires.2004.09.001, 15804389.
5. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991, 48:239-246.
6. Green M, Kern R, Heaton R. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004, 72:41-51. 10.1016/j.schres.2004.09.009, 15531406.
7. Tabarés-Seisdedos R, Balanzá-Martínez V, Sánchez-Moreno J, Martínez-Arán A, Salazar-Fraile J, Selva-Vera G, Rubio C, Mata I, Gómez-Beneyto M, Vieta E, et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affective Dis 2008, 109:286-299.
8. Mishara AL, Goldberg TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry 2004, 55:1013-1022. 10.1016/j.biopsych.2004.01.027, 15121486.
9. Mazur D, Hayes K. Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics. Arch Gen Psychiatry 1985, 34:633-644.
10. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 1990, 16:477-499.
11. Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:219-232. 10.1016/j.pnpbp.2004.11.004, 15694228.
12. Riedel M, Muller N, Spellmann I, Engel RR, Musil R, Valdevit R, Dehning S, Douhet A, Cerovecki A, Strassnig M, Möller HJ. Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2007, 257:402-412. 10.1007/s00406-007-0748-9, 17629725.
13. Harvey PD, Patterson L, Zongh K, Brechner M. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006, 163:1918-1925. 10.1176/appi.ajp.163.11.1918, 17074943.
14. Harvey PD, Siu CO. Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 2004, 172:324-332. 10.1007/s00213-003-1652-2, 14615877.
15. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, . CATIE Investigators; Neurocognitive Working Group Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64:633-647. 10.1001/archpsyc.64.6.633, 17548746, CATIE Investigators; Neurocognitive Working Group.
16. Spellmann I, Strassnig M, Douhet A, Dehning S, Opgen-Rhein M, Valdevit R, Engel RR, Kleindienst N, Müller N, Möller HJ. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 2007, 257:360-370. 10.1007/s00406-007-0739-x, 17629731.
17. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003, 28:1491-1500. 10.1038/sj.npp.1300216, 12799617.
18. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Antipsychotic drug exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry 2007, 62:818-821. 10.1016/j.biopsych.2006.10.031, 17300756.
19. Harvey PD, Keefe RS. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 2001, 158:176-184. 10.1176/appi.ajp.158.2.176, 11156796.
20. Goldberg TE, Goldman RS, Burdick KE, Malhotra AK, Lencz T, Patel RC, Woerner MG, Schooler NR, Kane JM, Robinson DG. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?. Arch Gen Psychiatry 2007, 64:1115-1122. 10.1001/archpsyc.64.10.1115, 17909123.
21. Woodward ND, Purdon SE, Meltzer H, Zaldh DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005, 8:457-472.
22. Harvey PD, Rabinowitz J, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry 2005, 95:1888-1895.
23. Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, Liebermann JA. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164:1061-1071. 10.1176/appi.ajp.164.7.1061, 17606658.
24. Tabarés-Seisdedos R, Balanzá-Martínez V, Pallardó Y, Salazar-Fraile J, Selva G, Vilela C, Vallet M, Leal C, Gómez-Beneyto M. Similar effect of family history of psychosis on Sylvian fissure size and auditory P200 amplitude in schizophrenic and bipolar subjects. Psychiatry Res 2001, 108:29-38. 10.1016/S0925-4927(01)00113-5, 11677065.
25. Tabarés-Seisdedos R, Salazar-Fraile J, Selva-Vera G, Balanza-Martínez V, Ballester-Sánchez F, Cózar-Santiago R, Leal-Cercós C, Gómez-Beneyto M. Abnormal motor asymmetry only during bimanual movement in schizophrenic patients compared with healthy subjects. Schizophr Res 2003, 61:245-253. 10.1016/S0920-9964(02)00286-4, 12729876.
26. Balanzá-Martínez V, Tabarés-Seisdedos R, Selva-Vera G, Martínez-Arán A, Torrent C, Salazar-Fraile J, Leal-Cercós C, Vieta E, Gómez-Beneyto M. Persistent cognitive dysfunctions in bipolar I disorder and schizophrenic patients: a three-year follow-up study. Psychother Psychosom 2005, 74:113-119. 10.1159/000083170, 15741761.
27. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. Washington DC 1994, 4, American Psychiatric Association.
28. Wing JK, Babor T, Brugha T, Cooper JE, Giel R, Jablenski A, Regier D, Sartorius N. SCAN. Schedules for Clinical Assessment in Neuropsychiatry. Arch Gen Psychiatry 1990, 47:589-593.
29. Marangell LB, Yudofsky SC, Silver JM. Antipsychotic drugs. Textbook of Psychiatry 1999, 1064. Wahington DC: American Psychiatric Press, Hales, RE, Yudofsky SC, Talbott JA, 3.
30. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 2003, 64:663-667. 10.4088/JCP.v64n0607, 12823080.
31. Kay SR, Fiszbein A, Vital-Herne M, Fuentes LS. The Positive and Negative Syndrome Scale-Spanish adaptation. J Nerv Ment Dis 1990, 178:510-517.
32. Peralta-Martín V, Cuesta-Zorita MJ. Validation of positive and negative symptom scale (PANSS) in a sample of Spanish schizophrenic patients. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1994, 22:171-177.
33. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
34. Ramos-Brieva JA, Cordero-Villafáfila A. New validation of the Hamilton Rating Scale for Depression. J Psychiatr Res 1998, 22:21-28.
35. Phillips L. Case history data and prognosis in schizophrenia. J Nerv Ment Dis 1953, 117:515-525. 10.1097/00005053-195306000-00004, 13109512.
36. Tabarés-Seisdedos R, Sanjuan-Arias J, Gómez-Beneyto M, Leal-Cercos C. Early age of onset, brain morphological changes and non-consistent motor asymmetry in schizophrenic patients. Schizophr Res 1999, 37:25-31.
37. Selva G, Salazar J, Balanzá-Martínez V, Rubio C, Daban C, Sánchez-Moreno J, Vieta E, Tabarés-Seisdedos R. Bipolar I patients with and without a history of psychotic symptoms: do they differ in their cognitive functioning?. J Psychiatr Res 2007, 41:265-272. 10.1016/j.jpsychires.2006.03.007, 16762369.
38. Ardila A, Rosselli M, Puente A. Neuropsychological Evaluation of the Spanish Speaker. 1994, Plenum Press, New York.
39. Woodward ND, Purdon SE, Meltzer HY, Zaldh DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 2007, 89:211-224. 10.1016/j.schres.2006.08.021, 17059880.
40. Wittorf A, Sickinger S, G Klingberg S. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic six-month follow-up study. Arch Clin Neuropsychol 2008, 23:271-282. 10.1016/j.acn.2007.12.005, 18272323.
41. Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, Asada T, Iidaka T. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1009-1014. 10.1016/j.pnpbp.2006.03.013, 16644082.
42. Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006, 85:222-231. 10.1016/j.schres.2006.03.033, 16679001.
43. Keefe RS, Seidman LJ, Christensen BK, Harmer RF, Sharma T, Sistskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, Lieberman JA. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004, 161:985-995. 10.1176/appi.ajp.161.6.985, 15169686.
44. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999, 25:233-235.
45. Newton S, Duman R. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007, 21:715-725. 10.2165/00023210-200721090-00002, 17696572.
46. Frey BN Gomes FA, Tramontina J, Kauer-Sant'anna M, Grassi-Oliveira R, Post RM. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008, 32:675-692. 10.1016/j.neubiorev.2007.10.005, 18199480.